Catalyst’s Firdapse (amifampridine) Receives FDA’s Approval for Lambert-Eaton Myasthenic Syndrome

 Catalyst’s Firdapse (amifampridine) Receives FDA’s Approval for Lambert-Eaton Myasthenic Syndrome

Catalyst’s Firdapse (amifampridine) Receives FDA’s Approval for Lambert-Eaton Myasthenic Syndrome


Shots:

  • The approval is based on two clinical trial results assessing Firdapse vs PBO in 64 patients with Lambert-Eaton Myasthenic Syndrome
  • The study measured Quantitative Myasthenia Gravis score (assessing muscle weakness) and demonstrated overall impression having effective results vs PBO
  • Firdapse (amifampridine) is an EU approved drug in Dec 2009, indicated for symptomatic treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) and has also received FDA’s PT, BT & ODD

Click here to read full press release/ article | Ref: Catalyst | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post